Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial

BACKGROUND: Anacetrapib is the only cholesteryl ester transfer protein inhibitor proven to reduce coronary heart disease (CHD). However, its effects on reverse cholesterol transport have not been fully elucidated. Macrophage cholesterol efflux (CEC), the initial step of reverse cholesterol transport...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Am Heart Assoc
Hlavní autoři: Metzinger, Mark P., Saldanha, Suzanne, Gulati, Jaskeerat, Patel, Kershaw V., El‐Ghazali, Ayea, Deodhar, Sneha, Joshi, Parag H., Ayers, Colby, Rohatgi, Anand
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955402/
https://ncbi.nlm.nih.gov/pubmed/33263263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.120.018136
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky